Gefitinib Tablets Exporter India | EGFR Inhibitor Lung Cancer Medicine Supplier

Product Overview
Key Features
Therapeutic Uses
Dosage Form Advantages

Gefitinib tablets are targeted anti-cancer medicines belonging to the epidermal growth factor receptor (EGFR) inhibitor class, primarily used in the treatment of non-small cell lung cancer. The formulation acts by blocking EGFR pathways, which are responsible for tumor cell proliferation and survival, thereby helping in slowing disease progression.

In the global pharmaceutical sourcing market, Gefitinib tablets exporter India and lung cancer medicine supplier India are highly searched by oncology distributors and importers. Genliva Wellness LLP, Himatnagar, operates as a pharma exporter India oncology medicines provider, supporting international clients with consistent supply of targeted therapy drugs and advanced cancer treatment formulations.

Gefitinib tablets are a targeted anticancer therapy designed as an EGFR tyrosine kinase inhibitor. The formulation helps block cancer cell growth signals, providing precise and effective treatment in selected lung cancer cases.

EGFR tyrosine kinase inhibitor for targeted cancer therapy
Blocks abnormal signaling pathways responsible for tumor growth
Oral dosage form for convenient administration
Designed for precision oncology treatment protocols
Supports consistent and controlled therapeutic response
Manufactured under stringent cGMP and quality standards

This medication is primarily used in oncology for the treatment of specific types of lung cancer with EGFR mutations. It is used under specialist supervision as part of targeted therapy regimens.

Non-small cell lung cancer (NSCLC) with EGFR mutation
Metastatic or advanced lung cancer cases
Second-line or targeted therapy in resistant cases
Used in personalized oncology treatment plans
Helps slow disease progression and improve outcomes

The formulation offers targeted action against cancer cells with improved tolerability compared to traditional chemotherapy options. It supports precision-based treatment approaches.

Targeted mechanism reduces impact on healthy cells
Oral therapy improves patient convenience
Suitable for long-term oncology management
Predictable pharmacological action
Stable formulation with consistent efficacy
Ideal for hospital supply and global oncology markets